A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)

NCT03448692

Last updated date
Study Location
New York University Grossman School of Medicine - CTSI
New York, New York, 10016, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Focal Segmental Glomerulosclerosis (FSGS)
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Adults age 18 years and older who have a confirmed diagnosis of FSGS.

2. Estimated glomerular filtration rate (eGFR) greater than or equal to 45 ml/min/1.73 m2. If eGFR is 30 - 45 ml/min/1.73 m2, a recent biopsy (within 12 months prior to Screening) must demonstrate < 50% tubulointerstitial fibrosis.

3. Urine protein:creatinine ratio (UPCR) greater than 1.5 g/g at screening.

4. Treated with at least one but not more than 3 classes of immunosuppressants either alone or in combination, or has a contraindication to use of an immunosuppressant or is intolerant to an immunosuppressant per investigator judgment

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


1. Diagnosis of collapsing FSGS.


2. Advanced chronic changes on renal biopsy as evidenced by greater than 50%
tubulointerstitial fibrosis.


3. Body mass index (BMI) greater than 45 kg/m2.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Focal Segmental Glomerulosclerosis (FSGS)A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)
NCT03448692
  1. New York, New York
  2. Lodz,
  3. Burela, Lugo
  4. Birmingham, Alabama
  5. Birmingham, Alabama
  6. Birmingham, Alabama
  7. Birmingham, Alabama
  8. Los Angeles, California
  9. Los Angeles, California
  10. Los Angeles, California
  11. Los Angeles, California
  12. Los Angeles, California
  13. Los Angeles, California
  14. Los Angeles, California
  15. Palo Alto, California
  16. Palo Alto, California
  17. San Francisco, California
  18. Stanford, California
  19. Stanford, California
  20. Miami, Florida
  21. Miami, Florida
  22. Miami, Florida
  23. Lawrenceville, Georgia
  24. Lawrenceville, Georgia
  25. Chicago, Illinois
  26. Chicago, Illinois
  27. Chicago, Illinois
  28. Lenexa, Kansas
  29. Boston, Massachusetts
  30. Boston, Massachusetts
  31. Boston, Massachusetts
  32. Boston, Massachusetts
  33. Kansas City, Missouri
  34. Kansas City, Missouri
  35. Flushing, New York
  36. Flushing, New York
  37. Chapel Hill, North Carolina
  38. Chapel Hill, North Carolina
  39. Chapel Hill, North Carolina
  40. Cincinnati, Ohio
  41. Cincinnati, Ohio
  42. Cincinnati, Ohio
  43. Cincinnati, Ohio
  44. Cincinnati, Ohio
  45. Columbus, Ohio
  46. Columbus, Ohio
  47. Columbus, Ohio
  48. Houston, Texas
  49. Houston, Texas
  50. Houston, Texas
  51. Edmonton, Alberta
  52. Edmonton, Alberta
  53. Pavia PV, Pavia
  54. Sendai, Miyagi
  55. Niigata,
  56. Warszawa,
  57. Warszawa,
  58. Barcelona,
  59. Barcelona,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)
Official Title  ICMJE A PHASE 2, 12 WEEK, ADAPTIVE, OPEN LABEL, SEQUENTIAL COHORT TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF 06730512 FOLLOWING MULTIPLE DOSES IN ADULT SUBJECTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)
Brief Summary The purpose of this Phase 2 adaptive study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of PF-06730512 following multiple intravenous infusion in adult subjects with FSGS.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Masking Description:
Open label
Primary Purpose: Treatment
Condition  ICMJE Focal Segmental Glomerulosclerosis (FSGS)
Intervention  ICMJE Drug: PF-06730512
Subjects in cohort 1 will receive Dose 1 Intravenous infusion (IV). Subjects in cohort 2 will receive Dose 2 IV.
Study Arms  ICMJE
  • Experimental: PF-06730512 Cohort 1
    Subjects in cohort 1 will receive dose 1 Intravenous (IV) infusion.
    Intervention: Drug: PF-06730512
  • Experimental: PF-06730512 Cohort 2
    Subjects in cohort 2 will receive dose 2 IV infusion.
    Intervention: Drug: PF-06730512
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: February 22, 2018)
44
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE May 1, 2023
Estimated Primary Completion Date May 1, 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Adults age 18 years and older who have a confirmed diagnosis of FSGS.
  2. Estimated glomerular filtration rate (eGFR) greater than or equal to 45 ml/min/1.73 m2. If eGFR is 30 - 45 ml/min/1.73 m2, a recent biopsy (within 12 months prior to Screening) must demonstrate < 50% tubulointerstitial fibrosis.
  3. Urine protein:creatinine ratio (UPCR) greater than 1.5 g/g at screening.
  4. Treated with at least one but not more than 3 classes of immunosuppressants either alone or in combination, or has a contraindication to use of an immunosuppressant or is intolerant to an immunosuppressant per investigator judgment

Exclusion Criteria:

  1. Diagnosis of collapsing FSGS.
  2. Advanced chronic changes on renal biopsy as evidenced by greater than 50% tubulointerstitial fibrosis.
  3. Body mass index (BMI) greater than 45 kg/m2.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Pfizer CT.gov Call Center1-800-718-1021[email protected]
Listed Location Countries  ICMJE Canada,   Italy,   Japan,   Poland,   Spain,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03448692
Other Study ID Numbers  ICMJE C0221002
2019-003607-35 ( EudraCT Number )
PODO ( Other Identifier: Alias Study Number )
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date January 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP